By Doug Macron

Rosetta Green last week announced it had added a second major ag-bio company to its list of collaborators, striking a deal with Bayer CropScience to discover and characterize microRNAs that can potentially be used to improve drought tolerance and yield in cotton.

Bayer will have exclusive access to targets identified through the arrangement. In exchange, Rosetta will receive undisclosed development and commercialization milestones, as well as royalties.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.